home / stock / tak / tak news


TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 05/07/24

Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...

TAK - Grifols: Why To Watch From The Sidelines

2024-05-07 05:10:21 ET Summary Grifols, a major player in global plasma extraction and processing, has experienced a significant 43% decline in stock price in 2024 following a bearish report from Gotham. KPMG and the Spanish regulator have offered a more favorable perspective base...

TAK - Exelixis: With Patent Litigation Decision Due Soon, There Are Options

2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...

TAK - Non-Farm Payrolls Preview For April 2024: 3 Major Considerations

2024-05-01 09:00:00 ET Summary April 2024 jobs report expected to show an increase of 250,000 jobs, indicating continued tightness in the labor market. Healthcare sector likely to add jobs, while drug manufacturers may struggle. Construction, government, energy, and beverage i...

TAK - Bristol, Sanofi, Takeda gain positive CHMP recommendations

2024-04-26 14:32:03 ET More on Bristol, Sanofi, Takeda Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript Sanofi 2024 Q1 - Results - Earnings Call Presentation Takeda s...

TAK - Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...

TAK - HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...

TAK - Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

2024-04-25 18:28:44 ET Summary Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder. NBI-1065845 may offer some advantages over currently approved MDD therapies, su...

TAK - These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

2024-04-25 17:49:16 ET Summary The Annual Meeting of the American Society of Clinical Oncology is a major event for clinicians and researchers in the field of oncology. The plenary session will feature presentations on topics such as esophageal cancer, melanoma, and lung cancer. ...

TAK - Takeda said to have left industry trade group BIO

2024-04-25 15:35:07 ET More on Takeda Pharmaceutical Takeda Pharmaceutical: Eohilia's FDA Approval Brings Tailwinds Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits Takeda Pharmaceutical Company Limited 2023 Q3 - Results - Earnings Call P...

TAK - Polaris International Equity Composite Q1 2024 Commentary

2024-04-25 08:30:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

Previous 10 Next 10